anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
About 15% of the general population shows resistance to the antiplatelet effects of aspirin, due to genetic polymorphisms and other factors. This resistance is a cause of increased myocardial infarction and death in patients undergoing percutaneous coronary interventions. Aspirin resistance can be detected by whole blood impedance aggregometry using the Multiplate® analyzer. The population of patients undergoing vascular surgery is at particular risk of suffering myocardial infarction in the perioperative period because of the high prevalence of risk factors. Most of these patients are treated by aspirin, as a measure of primary or secondary prevention. In this study we aim to establish baseline aspirin efficacy, as measured by the Multiplate® analyzer, in this high-risk population and evaluate the changes in aspirin efficacy over the first five days of the postoperative period. It is our hypothesis that the state of chronic inflammation, accompanying severe, generalized atherosclerosis results in a higher incidence of aspirin resistance in this population. Also, the surgical trauma and postoperative thrombocytosis may reduce the efficacy of aspirin in the postoperative period, partially explaining the increased incidence of postoperative myocardial infarction in this population.

In whole blood impedance aggregometry, the electrical impedance of the blood sample is measured by placing two electrodes in the recipient. After the addition of a platelet activator, the impedance will increase as platelets accumulate on the electrodes surfaces. Several activators, testing the patency of different platelet receptors can be used.

In this study, blood will be drawn on the day of surgery, and daily until the fifth postoperative day. Arachidonic acid, ADP, TRAP-6 and collagen will be used as activators. The first specifically tests the platelets reactivity to thromboxane A2. Aspirin inhibits this pathway, and the increase in impedance should therefore be limited in patients treated by this drug. The three other tests will be performed to evaluate the evolution of overall platelet reactivity in the postoperative period.
A concentrate for use in preparation of a medical solution for hemodialysis, hemodiafiltration, hemofiltration or peritoneal dialysis or an infusion solution. The concentrate comprises gluconic  acid and glucose. The concentrate is extremely concentrated in a  degree of concentration of at least 1:150. The concentrate is d iluted and mixed with a second solution comprising sodium bicarbonate, whereby the gluconic acid is used to adjust the medical solution to a physiological pH value of between 7.1 and 7.4. The gl uconic acid thus replaces the conventionally used acetic acid. T he invention also relates to the use of a concentrate comprising glucose and gluconic acid. The gluconic acid can be obtained by  dissolving glucono-lactone in powder form in water.
Antibacterial protein complexes designated as Anti-adhesive Lactalbumin Like Protein (ALLP) are obtained by ion-exchange chromatography of casein and alpha-lactalbumin. Casein isolated from human milk by acid precipitation is subjected to ion-exchange chromatography using an NaCl gradient to obtain six fractions. Fraction six contains the antibacterial protein complex and is recovered. Ion-exchange chromatography of human or bovine alpha-lactalbumin using an NaCl gradient resulted in a fraction that was retained and eluted that contained an antibacterial multimeric protein complex. The protein complexes inhibit attachment of  S. pneumoniae  and  H. influenzae  to human respiratory tract epithelial cells when tested in vitro, and the protein complexes can be used to treat a bacterial infection in the respiratory tract. The protein complexes are administered in a pharmaceutical composition or in a food or feed-stuff.
Participants in the treatment group underwent 30 minutes acupuncture (0.30mm×70mm) at Zusanli(ST36), Xiajuxu(ST39), Hegu(LI4), Neiguan(PC6) once a day for seven days. After"Deqi",electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) isconnected and maintained the end of treatment.
PURPOSE: A cosmetic composition containing flavonoid compounds for preventing aging and wrinkle is provided to enhance anti-oxidation, protein synthesis, and collagen synthesis, and to suppress MMP-1(Matrix Metalloprotease-1). CONSTITUTION: A cosmetic composition for anti-aging contains flavonoid compounds of chemical formula 1 as an active ingredient. In chemical formula 1, R1, R2, and R3 are independently hydroxyl group, alkyl group of 1-4 carbon atoms, or alkoxy group of 1-4 carbon atoms. A cosmetic composition for anti-wrinkle contains 0.000001-15.0 weight% of flavonoid compounds of chemical formula 1 as an active ingredient. The cosmetic composition is used in the form of solution, suspension, paste, gel, cream, lotion, powder, soap, oil, or spray. A make-up method for preventing anti-aging comprises a step of applying the cosmetic composition on human skin.
BACKGROUND: Total colonic aganglionosis (TCA) is a rare variant of Hirschsprung disease (HD) where the colon and portion of distal ileum lack ganglion cells. Most pediatric use either a straight ileoanal (Swenson or Yancey-Soave) or a short Duhamel pull-through for TCA. There are no large studies comparing these techniques. We aimed to compare short-and medium-term outcomes between these approaches.
METHOD: A retrospective review was performed among children with TCA from 2001 to 2019 undergoing a primary Duhamel or Swenson pull-through across three large children's hospitals. Patients undergoing redo and patients with greater than 30 % small bowel aganglionosis were excluded. We gathered data on demographics, operative approach, and outcomes at one, two, and three years. Continuous variables were analyzed with t-tests and categorical variables with Chi square or Fisher's tests.
RESULTS: There were 54 patients, with 26 (48 %) undergoing Duhamel and 28 (52 %) undergoing Swenson pull-through. There were no differences in sex, age, medical comorbidities, or operative details, including age at pull-through, laparoscopic vs open, length of involved small bowel, and operative time. Length of stay and post-operative complications were not different. Three years after pull-through, patients undergoing Duhamel had fewer stools per day (1-3 stools 69.6 % vs 14.3 %, p = 0.003) and were less likely to be prescribed fiber supplementation (4.2 % vs 43.8 %, p = 0.003). There were no differences in irrigations, botulinum toxin administration, loperamide, or HD admissions.
CONCLUSION: Both Duhamel and straight pull-throughs are safe for treatment of TCA, with acceptable short- and medium-term outcomes. Further studies on patient-reported outcomes are necessary to examine long-term differences.
LEVEL OF EVIDENCE: III.
Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
PURPOSE:To obtain the title neutral and soluble surfactant with less toxicity and irritating property by acylating the side-chain amine group of collagen or gelatin with a 2-26 C fatty acid and a 2-8 C dicarboxylic acid. CONSTITUTION:A fatty acid anhydride is added to a collagen or gelatin soln. to acylate the collagen or gelatin (about 5-40% acylation rate). A 2-26 C fatty acid is used and propionic acid, heptanic acid and myristic acid are preferably used. Then the material is acylated (about 60-95% acylation rate) by using a 2-8 C dicarboxylic acid anhydride. Succinic acid is preferably used as the dicarboxylic acid. The material is made lipophilic by the acylation with the fatty acid and made water-soluble in the neutral region by the acylation with the dicarboxylic acid. Acccordingly, the obtained surfactant can be utilized in the various fields of cosmetics, food, etc., which are mostly used in the neutral region.
Significant progress has been made with regard to understanding how the adult brain responds after a stroke. However, a large number of patients continue to suffer lifelong disabilities without adequate treatment. In the present study, we have analyzed possible microanatomical alterations in the contralesional hippocampus from the ischemic stroke mouse model tMCAo 12-14 weeks after transient middle cerebral artery occlusion. After individually injecting Lucifer yellow into pyramidal neurons from the CA1 field of the hippocampus, we performed a detailed three-dimensional analysis of the neuronal complexity, dendritic spine density, and morphology. We found that, in both apical (stratum radiatum) and basal (stratum oriens) arbors, CA1 pyramidal neurons in the contralesional hippocampus of tMCAo mice have a significantly higher neuronal complexity, as well as reduced spine density and alterations in spine volume and spine length. Our results show that when the ipsilateral hippocampus is dramatically damaged, the contralesional hippocampus exhibits several statistically significant selective alterations. However, these alterations are not as significant as expected, which may help to explain the recovery of hippocampal function after stroke. Further anatomical and physiological studies are necessary to better understand the modifications in the "intact" contralesional lesioned brain regions, which are probably fundamental to recover functions after stroke.
BACKGROUND: Tourniquets are common adjuncts in the operating theatre but can be associated with post-operative pain. This study was designed to compare what effect pre-tourniquet Esmarch bandage exsanguination has on pain, compared to pre-tourniquet exsanguination by elevation alone.
METHODS: 52 volunteers (104 lower limbs) were included in this study with each volunteer acting as their own matched control. The primary outcome was patient reported pain, measured in both legs simultaneously using area under curve. Secondary outcomes were pain score during inflation and deflation, cumulative pain score, duration of recovery and blood pressure during testing.
RESULTS: Pain after Esmarch was superior to elevation as measured by area under pain curve (68.9 SD 26.1 vs 77.2 SD 27.3, p = 0.0010), independent of leg dominance. Cumulative pain scores demonstrated the same superiority after inflation (50.7 SD 17.1 vs 52.9 SD 17.0, p = 0.026) but not after deflation (p = 0.59). Blood pressure was not significantly different. Time to full recovery of the lower limb was the same for both groups-7.6 min (SD 2.1 min, p = 0.80).
CONCLUSION: Previous studies describe a positive effect on pain when Esmarch bandage was used prior to tourniquet inflation for upper limb. Our findings suggest the same benefit from Esmarch when it was used on lower limbs-particularly during inflation of tourniquet. In addition to pain profiles, surgeon preference and patient factors need to be considered when deciding between elevation and Esmarch bandage.
Emerging highly pathogenic SARS-CoV-2 has caused the recent worldwide pandemic named COVID-19. Considerable efforts have been made for the development of effective vaccine strategies against COVID-19. Giving that the spike S protein plays a crucial role in eliciting the immune response during COVID-19 disease, the S protein has been the predominant candidate for the design of efficient vaccine candidates against SARS-CoV-2. The purpose of the inventors was to evaluate the antigenic reactivity of different synthetic peptides representing potential B-cell epitopes located in the S protein in relation to a BNT162b2 recipient serum. They identified the residues S 616-644  and S 1138-1169  as two potential B-cell epitopes in the S protein. Whereas BNT162b2 recipient serum as well as COVID19 donor serum were capable of reacting with a synthetic peptide representing the residues S 1138-1169 , a synthetic peptide representing the residues S 616-644  showed immunoreactivity only with a BNT162b2 recipient serum. In conclusion, the inventors showed that immunization with encapsulated mRNA vaccine BNT162b2 expressing a stabilized prefusion SARS-CoV-2 protein results in production of antibodies directed against the two B-cell epitopes that compose the residues S 616-644  and S 1138-1169 . The synthetic peptides representing the residues S 616-644  and S 1138-1169  have ability to react as antibody epitopes in relation to a BNT162b2 recipient serum and thus can be used for diagnostic and vaccine purposes.
A controlled release capsule comprises a male plug (2) formed of a water-swellable hydrogel which is engaged within a neck portion (4) of a female body (6). The capsule is intended to deliver two dosages of pharmaceutically active material at different times. A water soluble cap (8) is fitted over mouth (14) of the body, and defines a first volume (9) containing a first unit dosage (10). A second unit dosage (12) is contained within a second volume (11) defined by the plug and the female body. When the capsule is swallowed by a patient, the cap dissolves quickly in the aqueous medium within the gastro-intestinal tract and releases the first dosage. The aqueous medium then comes into contact with the hydrogel plug which swells and becomes disengaged from the body, usually in the intestine, thereby releasing the second dosage a predetermined time after the first dosage.
The invention belongs to the technical field of medical products, and discloses an application of DDX19A in promoting squamous cell carcinoma metastasis. Functionally, DDX19A was found to promote migration and invasion of cervical squamous cell carcinoma cells in vitro and lung metastasis in vivo. Mechanistically, overexpression of DDX19A increased NOX1 expression, increased reactive oxygen species ROS production, and induced cervical squamous cell carcinoma cell migration and invasion. Rescue experiments show that over-expression of NOX1 can save the knock-down of DDX19A, which causes cervical cancer squamous cell carcinoma cell invasion and migration and the generation of ROS, and further find that the ROS inhibitor N-acetylcysteine can inhibit the DDX 19A-induced cervical squamous cell carcinoma cell invasion and migration. It is thus demonstrated that DDX19A mediates ROS production by inducing NOX1, thereby promoting cervical squamous cell carcinoma metastasis. Blocking the DDX19A/NOX1/ROS axis may be a potential therapeutic target for cervical squamous cell carcinoma patients.
A case for coin tissue is disclosed. In one aspect, the case includes a drawer housing including an insertion space and a push-in and pull-out portion communicating with the insertion space. The case also includes a drawer configured to be pushed into or pulled out of the insertion space in a slidable manner through the push-in and pull-out portion. The drawer includes an upper opening portion. A plurality of coin tissues are placed in one or more rows in the drawer. The case further includes a pull-out distance limiting part provided between an inner surface of the drawer housing and an outer surface of the drawer, and configured to limit a pull-out distance of the drawer to a first distance. According to at least some embodiments, the case for coin tissue can sanitarily preserve a coin tissue, and is portable, and convenient.
Pleural effusion (PE) is a common yet challenging problem in clinical settings. PE is a symptom caused by over 50 diseases and is typically classified as either malignant pleural effusion (MPE) or benign pleural effusion (BPE). MPE affects a significant number of individuals, with an estimated annual incidence of 500-700 cases per million population. Metastatic cancer is the leading cause of MPE, and lung cancer accounts for approximately 37.5% of cases. The management of MPE is a major clinical challenge due to its association with a typically poor prognosis, with a median survival of only 3 to 12 months. However, predicting survival in MPE patients can be difficult due to significant heterogeneity in underlying malignancy and patient performance status. Therefore, accurate prognostication remains a significant challenge in the management of MPE.

Metabonomics is an analytical technique for detecting metabolites in biological samples and has been widely used in disease diagnosis and prognosis evaluation in recent years. The aim of this study is to use Metabonomics technology to compare and analyze the differences in metabolites between benign and malignant pleural effusion, and to explore its application in the prognosis evaluation of lung cancer patients with malignant pleural effusion.
Inflammation in hair follicles will reduce the effectiveness of minoxidil (MXD) in the treatment of androgen alopecia (AGA) caused by elevated androgen levels. To target multiple physiological and pathological processes in AGA, a novel natural bioactive compound modified transfersomes (MXD-Rg3@TFs) was prepared to replace cholesterol that may disrupt hair growth, with ginsenosides Rg3 (Rg3) that have anti-inflammatory effects on AGA. The effects of MXD, Rg3 and their combination on AGA were evaluated using dihydrotestosterone (DHT) induced human dermal papilla cells (DPCs), and the results showed that the combination of MXD and Rg3 can significantly promote the proliferation, reduce the level of intracellular ROS and inflammatory factors, and inhibit the aging of DHT induced DPCs. Compared with cholesterol membrane transfersomes (MXD-Ch@TFs), MXD-Rg3@TFs has similar deformability, smaller particle size and better stability. MXD-Rg3@TFs has also significant advantages in shortening telogen phase and prolonging the growth period of hair follicles in C57BL/6 mice than MXD-Ch@TFs and commercial MXD tincture. The prominent ability of MXD-Rg3@TFs to inhibit the conversion of testosterone to DHT and reduce the level of inflammatory factors suggested that Rg3 and MXD in MXD-Rg3@TFs have synergistic effect on AGA therapy. MXD-Ch@TFs with no irritation to C57BL/6 mice skin is expected to reduce the dose of MXD and shorten the treatment time, which would undoubtedly provide a promising therapeutic option for treatment of AGA.
BACKGROUND: The actin-binding protein anillin (ANLN) functions as an oncogene in various cancers but has not been fully studied in oral squamous cell carcinoma (OSCC). This study aimed to investigate the expression of ANLN in OSCC tissues and cell lines, to better understand its role in mediating proliferative, angiogenic, invasive, and metastatic capabilities in this type of cancer.
METHODS: ANLN mRNA and protein levels were assessed using qPCR and western immunoblotting. The expression intensity of ANLN was evaluated using immunohistochemical (IHC) staining. Biological functional assays were employed to characterize the behavior of OSCC cells influenced by ANLN. Additionally, comprehensive bioinformatics analysis, including GO analysis and KEGG enrichment analysis, was performed on differentially expressed genes in ANLN-mediated pathways.
RESULTS: OSCC tumors and cell lines exhibited higher ANLN expression. Silencing of ANLN significantly suppressed OSCC cell proliferation, as evidenced by a significant reduction in the Ki-67 index both in vitro and in vivo. The migration and invasive ability of OSCC cells were markedly diminished, coinciding with a decrease in epithelial-mesenchymal transition activity. ANLN was also found to promote angiogenic activity in OSCC cells, partly through synergistic effects mediated by vascular endothelial growth factor A (VEGFA). Downregulation of ANLN expression led to decreased VEGFA levels, resulting in reduced angiogenesis characterized by fewer vascular branches.
CONCLUSIONS: Our findings highlight the promising role of ANLN as a biomarker for both diagnostic and prognostic in OSCC. Targeting ANLN with inhibitory strategies could impede the oncogenesis processes at the core of OSCC development, presenting significant opportunities for advancing therapeutic interventions.
BACKGROUND: High-intensity statin therapy is currently recommended initial guideline therapy in ACS treatment. However, only a minority of patients are achieving LDL-C attainment goal at 6 months. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are on recommended guideline therapy post-ACS if LDL-C goal attainment is not achieved after high-intensity statin (4-6 weeks) and after the addition of ezetimibe if guideline goal attainment is not achieved after an additional 4-6 weeks. Thus, it has been recommended that PCSK9 inhibitors be considered earlier post-ACS. However, the efficacy of early PCSK9 inhibitors initiation in ACS patients remains uncertain.
METHODS: This systematic review and meta-analysis was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) and observational studies involving ACS patients who received PCSK9 inhibitors within 48 h of hospitalization were included. Common and random effects models were used to evaluate the pooled effect of early PCSK9 inhibitor administration. Nine RCTs and three cohort studies were included.
RESULTS: Early PCSK9 inhibitor administration reduced the incidence of MI, ACS hospitalization, and revascularization at 6-18 months post-ACS. Although there was a drift towards reduced stroke, all-cause mortality, and cardiovascular death, no statistically significant reduction was observed. Additionally, PCSK9 inhibitors significantly enhanced lipid control at 4-12 weeks after index hospitalization.
CONCLUSION: Early PCSK9 inhibitors initiation in ACS patients reduces MACE and improves lipid profiles. While the results propose promising benefits in terms of stroke and mortality, further research with longer follow-up is required for more decisive evidence.
Background: Radiofrequency (RF) catheter ablation (CA) is an effective therapeutic strategy in eliminating refractory idiopathic ventricular outflow tract (OT) ventricular arrhythmias (VA). However, early and late recurrences occur commonly. RFCA has also been reported to be associated with collateral damage and pain. The use of Cryo ablation as a safer alternative energy source been previously described. In several reports Cryo was reported to successfully treat VA originating from the OT in the absence of ablation related pain and collateral damage to adjacent structures such as the coronaries. When comparing outcomes and complications of catheter ablation of VA from the papillary muscles of the left ventricle with either Cryo or RF, Cryo was found to be associated with significantly higher success rates and lower recurrence rates than RFCA.

Aim: To compare the outcomes and safety of Cryo vs. RF for PVCs. Methods: Patients with PVC VA will be randomized in a 1:1 fashion to RFCA or Cryo ablation. All procedures will be done using a 3-dimensional mapping system (EnSite™ NavX™ system, St. Jude Medical). Ablation will be performed at sites with earliest activation or at least pacemap exhibiting QRS morphology match of \>11/12. Endpoint of procedure will be elimination and non inducibility of the clinical VA. All patients will undergo continuous monitoring for at least 12 hours post procedure and 12 lead Holter and exercise testing 1 month post procedure. Successful ablation will be defined as absence of clinical VA or \> 50% reduction in arrhythmia burden on Holter in the absence of anti-arrhythmic medications.
PURPOSE:To provide the titled composition containing a physiologically active substance such as theophylline, etc. in combination with lecithin as active components, having low rate of release of the active component and long durability, formable easily in the form of medicinal drug with easy quality control and capable of releasing the active substance uniformly at a constant rate. CONSTITUTION:A physiologically active substance and lecithin are used as active components. The lecithin is e.g. soybean lecithin, yolk lecithin, refined lecithin, etc., and is used a drug base singly or in combination with other oily component such as a conventional component for the preparation of encapsulated medicine, e.g. an oily agent, a liquid fatty acid, etc. The amount of lecithin to be compounded depends upon the kind of lecithin and the active substance, and is preferably >=0.5wt%, especially 1-95wt%. The composition can be produced e.g. by dispersing the active substance in the form of fine powder in a base containing the lecithin.